We are live on ! Find out more
SCNI

Scinai Immunotherapeutics
SCNI

9 hedge funds and large institutions have $309K invested in Scinai Immunotherapeutics in 2023 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 0 increasing their positions, 4 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more first-time investments, than exits

New positions opened: 2 | Existing positions closed: 1

13% more funds holding

Funds holding: 8 → 9 (+1)

8.92% less ownership

Funds ownership: 20.59% → 11.67% (-8.9%)

63% less capital invested

Capital invested by funds: $839K → $309K (-$530K)

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 4

Holders
9
Holders Change
+1
Holders Change %
+12.5%
% of All Funds
0.14%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
–
Reduced
4
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$18.8K
2
RhumbLine Advisers
RhumbLine Advisers
Massachusetts
+$6.04K

Top Sellers

Rank Fund Capital Flow
1
SM
Sabby Management
Florida
-$233K
2
Millennium Management
Millennium Management
New York
-$55.3K
3
VF
Virtu Financial
New York
-$23K
4
UBS Group
UBS Group
Switzerland
-$8.64K
5
Morgan Stanley
Morgan Stanley
New York
-$173

SCNI Hedge Fund Activity: Q2 2023 in Review

9 of the 6,383 institutional investors tracked by Wall St. Rank reported a position in Scinai Immunotherapeutics (SCNI) for Q2 2023, worth a combined $309K — down 63% from $839K a quarter earlier.

Buyers outnumbered sellers: 2 funds opened new SCNI positions and 1 closed out — a net gain of 1 holder — while 0 added to existing stakes and 4 trimmed.

The largest buyer was Susquehanna International Group, opening a new position worth an estimated $18.8K. The largest seller was Sabby Management, cutting an estimated $233K.

  • 9 institutional investors held Scinai Immunotherapeutics (SCNI) as of Q2 2023, up from 8 in Q1 2023.
  • Funds reported $309K of Scinai Immunotherapeutics stock for Q2 2023, down 63% quarter-over-quarter.
  • 2 funds opened new Scinai Immunotherapeutics positions in Q2 2023 and 1 closed out, a net change of +1 holder.
  • The largest Scinai Immunotherapeutics buyer in Q2 2023 was Susquehanna International Group, an estimated $18.8K added.
  • The largest Scinai Immunotherapeutics seller in Q2 2023 was Sabby Management, an estimated $233K sold.

Based on aggregated 13F filings for Q2 2023.